<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347708</url>
  </required_header>
  <id_info>
    <org_study_id>DGX-A01</org_study_id>
    <nct_id>NCT03347708</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration</brief_title>
  <official_title>A Prospective, Randomized, Double‑Blinded, Vehicle‑ and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects With Single‑Level, Symptomatic Lumbar Intervertebral Disc Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiscGenics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DiscGenics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and preliminary efficacy of intradiscal
      injections of two doses of IDCT (Discogenic Cells + Sodium Hyaluronate vehicle) and two
      controls (saline, Sodium Hyaluronate vehicle) in subjects with chronic low back pain due to
      Degenerative Disc Disease (DDD) at one lumbar level from L3 to S1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, first‑in‑human, randomized, double‑blind, vehicle and placebo-controlled,
      parallel‑group, multi-center study in subjects with single‑level, symptomatic lumbar
      intervertebral disc degeneration (&gt;6 months) and unresponsive to conservative therapy for at
      least 3 months. The study will compare single intradiscal injections of high and low dose
      IDCT with two control groups (saline, Sodium Hyaluronate).

      8 study visits will be completed by all subjects; screening, day 1 (injection day), week 4,
      week 12, week 26, week 52, week 72 and week 104. The subject will be assessed for safety and
      efficacy utilizing VAS and ODI questionnaires alongside radiographic evaluations. The study
      will have a 1 year follow-up and a 1 year extension period (total 2 years).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by number of Adverse Events</measure>
    <time_frame>2 Years</time_frame>
    <description>To evaluate the safety and tolerability of a single injection of IDCT in subjects with single‑level, symptomatic early to moderate lumbar intervertebral disc degeneration as measured by the incidence of grade 2 or greater AEs and SAEs observed from Day 1 to week 104</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (Pain)</measure>
    <time_frame>1 Year</time_frame>
    <description>Evaluate the effect of IDCT on pain as measured by a 0-100mm Visual Analogue Scale (VAS). 0: no pain, 100: worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>2 Years</time_frame>
    <description>Evaluate the effect of IDCT on disability as measured by the Oswestry Disability Index (ODI). Score of 0%: no disability, score of 100%: severely disabled</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory</measure>
    <time_frame>2 Years</time_frame>
    <description>Imaging parameters will be evaluated via radiological evaluations</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>High Dose IDCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intradiscal injection with High Dose IDCT (9M cells).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose IDCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intradiscal injection with Low Dose IDCT (3M cells).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intradiscal injection with saline solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Hyaluronate Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intradiscal injection with Sodium Hyaluronate Vehicle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IDCT</intervention_name>
    <description>Discogenic Cells + Sodium Hyaluronate Vehicle</description>
    <arm_group_label>High Dose IDCT</arm_group_label>
    <arm_group_label>Low Dose IDCT</arm_group_label>
    <other_name>Progenitor Cells, Stem Cells, Allogeneic Cell Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>Sodium Chloride Solution</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline injection, Placebo control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate</intervention_name>
    <description>Sodium Hyaluronate Vehicle</description>
    <arm_group_label>Sodium Hyaluronate Vehicle</arm_group_label>
    <other_name>Sodium Hyaluronate injection, Hyaluronate Acid, Sodium Hyaluronate Solution Vehicle control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: The subject must have:

          1. Diagnosis of early to moderate degenerative disc disease (DDD), Modified Pfirrmann
             Grade 3-7.

          2. Chronic low‑back pain for at least 6 months prior to screening; unresponsive to at
             least 3 months of conservative care.

          3. Low‑back pain of 40 to 90 mm on the VAS and ODI score of 30 to 90.

        Exclusion Criteria: The subject is excluded if he/she has:

          1. Symptomatic involvement of more than one lumbar disc.

          2. Other persistent pain/nerve issues including, for example, radiculopathy, leg pain,
             cauda equine syndrome, etc.

          3. Fracture of the spine, previous lumbar spine surgery or previous treatment of the
             target disc.

          4. Evidence of dynamic instability on lumbar flexion‑extension radiographs.

          5. Grade 2 or higher spondylolisthesis at the target disc, lumbar spondylitis or other
             undifferentiated spondyloarthropathy, or Type III Modic changes around the target
             disc.

          6. Clinical suspicion of a full thickness annular tear at the target disc or other
             abnormal disc morphology.

          7. Clinical suspicion of facet pain as primary pain generator.

          8. Subjects who test positive for communicable disease, have significant systemic
             disease, or are prone to infection.

          9. Patients who are deemed unsuitable for clinical study participation by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego CIRM Alpha Stem Cell Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Source Healthcare</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otrimed</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spine Institute of Louisiana</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Center of St. Louis</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ainsworth Institute of Pain Management</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Neurosurgery &amp; Spine Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigations, LLC</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmes Murphey</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians' Research Options, LLC</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia iSpine</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.discgenics.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lumbar disc degeneration</keyword>
  <keyword>Low back pain</keyword>
  <keyword>Intervertebral disc degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

